Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
NCT05703685Phase 1Recruiting
- Sponsor
- National Institute of Mental Health
- Start
- Jun 2023
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]PF-06445974 in major depressive disorder (MDD), sponsored by National Institute of Mental Health. Primary endpoint: PDE4B density (distribution volume VT) at 36 months. Started Jun 2023; status: recruiting.
02
Drugs
[18F]PF-06445974
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05703685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703685.